Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy
Journal of Urology | October 13, 2021 | Volume: 207 | Issue: 3 | Pages: 541-550
10.1097/ju.0000000000002261
| PMID 34643090